18 unknown, 8 completed, 2 terminated, 1 active not recruiting. 8 Not applicable, 7 Phase 2, 6 Phase 4, 4 Phase 3, 3 Early Phase 1.
Follow KH902 fusion protein: new trials by email Literature Review of KH902 fusion protein trials Research Report on KH902 fusion protein
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection conbercept ophthalmic injection （0.5mg）, Faricimab - Proliferative Diabetic Retinopathy | Not applicable | Completed | Bojie Hu | 8 | 2024-12-01 | 2025-08-28 |
| Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy Conbercept - Retinopathy of Prematurity (ROP) | Not applicable | Recruiting | Wang Yusheng | 146 | 2024-11-29 | 2026-07-30 |
| Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy Conbercept - Diabetic Macular Edema | Phase 4 | Active not recruiting | Shanghai Eye Disease Prevention and Treatment Center | 58 | 2024-04-01 | 2025-05-30 |
| Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema Vitrectomy combined with ILM peeling, Conbercept intravitreal injection - Diabetic Macular Edema, Pars Plana Vitrectomy | Not applicable | Unknown | Tianjin Medical University Eye Hospital | 102 | 2024-03-05 | 2024-03-06 |
| Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use - Proliferative Diabetic Retinopathy | Phase 2 | Unknown | Peking University Third Hospital | 80 | 2022-04-01 | 2022-12-14 |
| Anti-VEGF in Real-world Ranibizumab, Aflibercept, Conbercept - Neovascular Age-related Macular Edema, Diabetic Macular Edema | Unknown | Wenbin Wei | 1000 | 2022-01-01 | 2022-02-03 | |
| Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy preoperative intravitreal injections of ranibizumab or conbercept - Proliferative Diabetic Retinopathy | Not applicable | Completed | Peking University People's Hospital | 80 | 2021-09-01 | 2022-06-10 |
| Evaluation of RC28-E Injection in Diabetic Macular Edema intravitreal injection of RC28-E, Conbercept - Diabetic Macular Edema | Phase 2 | Completed | RemeGen Co., Ltd. | 156 | 2021-03-17 | 2023-12-18 |
| Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema Conbercept intravitreal injection - Diabetic Macular Edema, Diabetic Retinopathy | Not applicable | Unknown | Eye & ENT Hospital of Fudan University | 40 | 2021-01-01 | 2020-12-16 |
| Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE) Conbercept and TA, Conbercept - Diabetes Mellitus, Type 2, Macular Edema | Not applicable | Unknown | Zhongshan Ophthalmic Center, Sun Yat-sen University | 50 | 2020-11-12 | 2020-11-17 |
| Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy KH903 + Paclitaxel, Placebo + Paclitaxel - Gastric Cancer, Gastroesophageal Cancer | Phase 2 | Unknown | Chengdu Kanghong Biotech Co., Ltd. | 81 | 2020-09-15 | 2020-09-18 |
| Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy intravitreal injection of conbercept, PRP - Proliferative Diabetic Retinopathy | Not applicable | Unknown | Sun Yat-sen University | 226 | 2019-10-12 | 2021-02-25 |
| PRP vs PRP+IVC for Severe nPDR Conbercept, Panretinal coagulation - Severe Nonproliferative Diabetic Retinopathy, Diabetic Retinopathy | Not applicable | Unknown | Ruijin Hospital | 40 | 2019-01-18 | 2019-03-05 |
| Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection - Neovascular Age-related Macular Degeneration | Phase 3 | Terminated | Chengdu Kanghong Biotech Co., Ltd. | 1157 | 2018-12-21 | 2021-06-23 |
| Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection - Neovascular Age-related Macular Degeneration | Phase 3 | Terminated | Chengdu Kanghong Biotech Co., Ltd. | 1157 | 2018-09-25 | 2021-06-24 |
| Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma conbercept - Circumscribed Choroidal Haemangioma | Early Phase 1 | Unknown | Sun Yat-sen University | 50 | 2018-06-06 | 2018-06-27 |
| Conbercept for Polypoidal Choroidal Vasculopathy（START Study） Conbercept - Polypoidal Choroidal Vasculopathy, Conbercept | Completed | Peking Union Medical College Hospital | 500 | 2018-05-01 | 2022-02-08 | |
| Initial Versus Delayed PDT Combination With Conbercept in PCV conbercept, Initial PDT, Delayed PDT - Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | The Eye Hospital of Wenzhou Medical University | 80 | 2017-01-01 | 2019-07-19 |
| Intravitreal Conbercept After Vitrectomy Conbercept - Early Proliferative Diabetic Retinopathy | Early Phase 1 | Completed | Tianjin Medical University Eye Hospital | 50 | 2017-01-01 | 2019-04-30 |
| Conbercept in Choroidal Neovascularization Secondary to Uveitis Conbercept, sham - Choroidal Neovascularization, Uveitis | Phase 2 | Unknown | Chongqing Medical University | 40 | 2016-11-01 | 2016-10-17 |
Showing 20 of 30. Sign in to see all of them.
Polypoidal Choroidal Vasculopathy (3) · Diabetic Retinopathy (2) · Macular Degeneration (2) · Retinal Vein Occlusion (2) · Choroidal Neovascularization (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Macular Edema (1) · Retinopathy of Prematurity (1) · Stomach Neoplasms (1) · Uveitis (1)
Chengdu Kanghong Biotech Co., Ltd. (8) · Sun Yat-sen University (3) · Ruijin Hospital (2) · Tianjin Medical University Eye Hospital (2) · Bojie Hu (1) · Chongqing Medical University (1) · Eye & ENT Hospital of Fudan University (1) · Jiao Mingfei (1) · Novartis Pharmaceuticals (1) · Peking Union Medical College Hospital (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · RemeGen Co., Ltd. (1) · Shanghai Eye Disease Prevention and Treatment Center (1) · The Eye Hospital of Wenzhou Medical University (1)
China (25) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Chile (1) · Colombia (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hong Kong (1)
Chenjin Jin, Ph.D. (2) · Yan Cheng, MD, PhD (2) · Bingqian Liu, MD, PhD (1) · Chenjin Jin, Dr. (1) · Huijin Chen, Dr. (1) · Jin Yang, MD, ph.D. (1) · Jinfeng Qu, MD (1) · Qiong Zhang, MD (1) · Rong X Li, MD,PhD (1) · Tao Sun (1) · Wenbin Wei, MD (1) · Xi Shen, MD (1) · Xi Shen, PhD (1) · Xiaodong Sun (1)
PMID 21438852, PMID 23706949, PMID 28902334, PMID 29104958, PMID 29127949, PMID 34001667, PMID 35223882, PMID 35795633, PMID 36451252, PMID 37021018, PMID 37875997, PMID 39207600, PMID 40122579